- Zymeworks appointed Kristin Stafford as chief financial officer, effective April 1, 2026.
- Stafford most recently served as senior vice president, chief accounting officer at Royalty Pharma, a role she held since December 2018.
- Her earlier posts include vice president, finance at Royalty Pharma and CFO at BioPharma Credit from 2016 to 2018.
- She previously worked at Ernst & Young in London on U.S. capital markets transactions for European life sciences companies.
- Stafford is a board member at Novocure.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zymeworks Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604010600OMX_____CNEWS_EN_GNW9682461_en) on April 01, 2026, and is solely responsible for the information contained therein.
Comments